Laboratoire Suisse d'Analyse du Dopage, Centre Universitaire Romand de Médecine Légale, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Croisettes 22, 1066 Epalinges, Switzerland.
J Pharm Biomed Anal. 2009 Dec 5;50(5):954-8. doi: 10.1016/j.jpba.2009.06.038. Epub 2009 Jun 27.
C.E.R.A., a continuous erythropoietin receptor activator, is a new third-generation erythropoiesis-stimulating agent (ESA) that has recently been linked with abuse in endurance sports. In order to combat this new form of doping, we examined an enzyme-linked immunosorbent assay (ELISA) designed to detect the presence of C.E.R.A. in serum samples. The performance of the assay was evaluated using a pilot excretion study that involved six subjects receiving C.E.R.A. Validation data demonstrated an excellent reproducibility and ensured the applicability of the assay for anti-doping purposes. To maximize the chances of detecting the drug in serum samples, we propose the use of this specific ELISA test as a high-throughput screening method, combined with a classic isoelectric focusing test as a confirmatory assay. This strategy should make C.E.R.A. abuse relatively easy to detect, thereby preventing the future use of this drug as a doping agent.
C.E.R.A.,一种持续的红细胞生成素受体激活剂,是一种新型的第三代促红细胞生成素刺激剂(ESA),最近与耐力运动中的滥用有关。为了打击这种新型的兴奋剂,我们检测了一种设计用于检测血清样本中 C.E.R.A.存在的酶联免疫吸附测定(ELISA)。该测定的性能使用涉及六名接受 C.E.R.A.的受试者的排泄研究进行评估。验证数据表明该测定具有极好的重现性,并确保了该测定可用于反兴奋剂目的。为了最大程度地提高在血清样本中检测到该药物的可能性,我们建议将该特定的 ELISA 测试用作高通量筛选方法,同时将经典等电聚焦测试用作确认性测定。这种策略应该使 C.E.R.A.滥用相对容易检测,从而防止将来将这种药物用作兴奋剂。